Keywords
diabetes mellitus
cardiovascular diseases
apolipoprotein A1
apolipoprotein B
C-reactive protein
interleukin-6
How to Cite
Abstract
Diabetes mellitus (DM) and cardiovascular diseases (CVDs) are factors that, on the one hand, complicate the course of COVID-19 (COronaVIrus Disease 2019), and on the other hand, provoke further complications of these diseases.
Aim. The aim of the study was to determine the level of apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), lipids, C-reactive protein (CRP) and interleukin-6 (IL-6) in the blood of 122 patients with DM and COVID-19 2-3 years after the disease.
Material and methods. ApoA1, ApoB, CRP, IL-6, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides (TG) were measured using ELISA kits (Elabscience, USA).
Results. Determination of the impact of COVID-19 on the level of ApoA1 and ApoB in the blood plasma of patients with DM 2-3 years after the disease showed that only the level of ApoB changed significantly. At the same time, the ApoB/ApoA1 ratio, which indicates the risk of CVDs, increased from 0.361 to 0.404. Gender differences in blood plasma levels of ApoA1 and ApoB in patients with DM and COVID-19 were noted for ApoA1, and the level of ApoA1 varied depending on the type of DM. The study of apolipoproteins content dependence on the body mass index and the level of glycated hemoglobin (HbA1c) showed a decrease in the ApoA1 and an increase in the ApoB concentration in people with a body mass index over 30 kg/m2 and with HbA1c concentration of more than 7%. Determination of COVID-19 effect on the lipid profile in blood plasma
of patients with DM 2-3 years after the disease showed that the levels of LDL and TG significantly increased, and the level of HDL decreased. At the same time, there was no difference between the mild and severe course of COVID-19.
Conclusion. There is a significant weakening of the body's response to the amplitude of changes in the lipids and, especially, apolipoproteins
concentration in the blood of patients who contracted COVID-19 2-3 years ago compared to the acute disease.
References
Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. Clin Investig Arterioscler. 2021 May-Jun;33(3):151-157. English, Spanish. doi: 10.1016/j.arteri.2020.10.001.
Liu Y, Lou X. The bidirectional association between metabolic syndrome and long-COVID-19. Diabetes Metab Syndr Obes. 2024 Oct 9;17:3697-710. doi: 10.2147/DMSO.S484733.
Mukkawar RV, Reddy H, Rathod N, Kumar S, Acharya S. The long-term cardiovascular impact of COVID-19: pathophysiology, clinical manifestations, and management. Cureus. 2024 Aug 10;16(8):e66554. doi: 10.7759/cureus.66554.
Sharma SK, Mohan A, Upadhyay V. Long COVID syndrome: An unfolding enigma. Indian J Med Res. 2024 Jun;159(6):585-600. doi: 10.25259/IJMR_1449_23.
Greenhalgh T, Sivan M, Perlowski A, Nikolich JŽ. Long COVID: a clinical update. Lancet. 2024 Aug 17;404(10453):707-24. doi: 10.1016/S0140-6736(24)01136-X.
Rye KA, Barter PJ, Cochran BJ. Apolipoprotein A-I interactions with insulin secretion and production. Curr Opin Lipidol. 2016 Feb;27(1):8-13. doi: 10.1097/MOL.0000000000000253.
Tronko ND, Pushkarev VM, Sokolova LK, Pushkarev VV, Kovzun OI. Molecular mechanisms of pathogenesis of diabetes and its complications. Publishing house Medkniga, Kyiv, 2018. 264 p. Russian.
Fritzen AM, Domingo-Espín J, Lundsgaard AM, Kleinert M, Israelsen I, Carl CS, et al. ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα2. Mol Metab. 2020 May;35:100949. doi: 10.1016/j.molmet.2020.01.013.
Dong H, Chen W, Wang X, Pi F, Wu Y, Pang S, et al. Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study. Metab Brain Dis. 2015 Dec;30(6):1319-30. doi: 10.1007/s11011-015-9732-7.
Mao Y, Xu Y, Lu L. The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes. Medicine (Baltimore). 2017 Jan;96(1):e5834. doi: 10.1097/MD.0000000000005834.
Pushkarev VV, Sokolova LK, Cherviakova SA, Belchina YB, Kovzun OI, Pushkarev VM. Plasma apolipoproteins A1/B and oxLDL levels in patients with COVID-19 as possible markers of the disease. Cytol Genet. 2021;55(6):519-23. doi: 10.3103/S0095452721060116.
Tronko MD, Cherviakova SA, Pushkarev VV, Belchina YB, Kovzun OI, Pushkarev VM, et al. Apolipoprotein A1 level in plasma of patients with diabetes and diabetic patients with COVID-19 as a possible marker of disease. Reports of the National Academy of Sciences of Ukraine. 2021;4:110-3. doi: 10.15407/dopovidi2021.04.110.